LAUSR

Invasive fungal diseases (IFD) are a major cause of morbidity and mortality in immunocompromised children, especially those undergoing allogeneic hematopoietic stem cell transplantation (HSCT) [1].Recently Vicenzi et al highlighted the role of posaconazole oral suspension in IFD prophylaxis and treatment in hemato/oncological children, reaching acceptable plasma levels in both groups [2].Although posaconazole is not approved in patients <18 years of age, it has been introduced in guidelines for IFD prophylaxis in children aged > 13 years [1]. Until 2013 oral suspension was the only formulation available, but its absorption is variable and depends on several conditions (e.g. the consumption of a fatty or acid meal), even if it has been demonstrated effective in different pediatric ages [2]. This article is protected by copyright. All rights reserved.